The present invention relates to the field of biochemistry, specifically to the bioproduction of glycolate. Host cells, especially cyanobacteria of the genus Synechocystis, are modified in several ways to increase extracellular glycolate, including: mutant Rubisco enzymes, overexpression of phosphoribulokinase (PRK) or phosphoglycolate phosphatase (PGP), a permease to export glycolate, like GIcA, or by reduction of the capacity to metabolize glycolate due to reduced or eliminated glycolate dehydrogenase, glycolate oxidase activity and/or lactate dehydrogenase.

The present invention relates to autotrophic microorganisms with altered photorespiration and improved CO.sub.2 fixation as well as a method of producing said autotrophic microorganisms. Particularly, the autotrophic microorganisms show an improved growth rate, productivity and energy conversion efficiency.

The present invention relates to autotrophic microorganisms with altered photorespiration and improved CO.sub.2 fixation as well as a method of producing said autotrophic microorganisms. Particularly, the autotrophic microorganisms show an improved growth rate, productivity and energy conversion efficiency.

The present application relates to the field of neurological diseases, particularly to dystonia, even more particularly to primary dystonia, most particularly DYT1 primary dystonia. It is disclosed that the DYT1 dystonia causative mutation in TORSIN1A leads to hyperactivation of LIPIN. The invention provides substances modulating LIPIN function, in particular RNA molecules inhibiting LIPIN function and medical uses of these LIPIN inhibitors. Methods are disclosed to screen for medicaments that counteract the effects of TORSIN1A mutation.